2001 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Kelsen
    Kelsen
  4. Saltz
    Saltz
  5. Norton
    Norton
  6. Bajorin
    Bajorin
  7. Kemeny
    Kemeny
  8. Scher
    Scher
  9. Ilson
    Ilson
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)
  7. Gastrointestinal Oncology Service (315)
  8. Epidemiology and Biostatistics (251)
  9. Genitourinary Oncology Service (233)
  10. Biostatistics Service (223)
  1. "antineoplastic combined chemotherapy protocols"
Formats
  1. Journal Article (1861)
  2. Conference Paper (49)
  3. Review (39)
  4. Editorial (17)
  5. Research Letter (15)
  6. Miscellaneous (8)
  7. Correspondence (6)
  8. Guidelines (5)
  9. Book Section (1)
Groups
  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)

More Groups

People
  1. Nancy Kemeny (90)
  2. Robert Motzer (88)
  3. Clifford Hudis (83)
  4. David Kelsen (83)
  5. Leonard Saltz (79)
  6. Larry Norton (77)

More People

Years
  1. 2025 (46)
  2. 2024 (133)
  3. 2023 (122)
  4. 2022 (90)
  5. 2021 (11)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (279)
  2. Cancer (171)
  3. Clinical Cancer Research (78)
  4. Seminars in Oncology (59)
  5. Gynecologic Oncology (58)
  6. New England Journal of Medicine (58)

More Publications

Publishers
  1. American Society of Clinical Oncology (294)
  2. Elsevier Inc. (276)
  3. Wiley Blackwell (212)
  4. Springer (167)
  5. Oxford University Press (113)
  6. American Association for Cancer Research (108)

More Publishers

Results (2001)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic value of (18)F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen
    Journal Article

    Michaud, L.; Bantilan, K.; Mauguen, A.; Moskowitz, C. H.; Zelenetz, A. D.; Schòˆder, H.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Randomized phase III trial of ganitumab with interval-compressed chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma: A report from the Children's Oncology Group
    Journal Article

    DuBois, S. G.; Krailo, M. D.; Glade-Bender, J.; Buxton, A.; Laack, N.; Randall, R. L.; Chen, H. X.; Seibel, N. L.; Boron, M.; Terezakis, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial
    Journal Article

    Tempero, M. A.; Pelzer, U.; O'Reilly, E. M.; Winter, J.; Oh, D. Y.; Li, C. P.; Tortora, G.; Chang, H. M.; Lopez, C. D.; Bekaii-Saab, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Genomic biomarkers associated with response to induction chemotherapy in patients with localized pancreatic ductal adenocarcinoma
    Journal Article

    Ecker, B. L.; Tao, A. J.; Janssen, Q. P.; Walch, H. S.; Court, C. M.; Balachandran, V. P.; Crane, C. H.; D'Angelica, M. I.; Drebin, J. A.; Kingham, T. P.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Soft-Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe
    Review

    Lautz, T. B.; Martelli, H.; Fuchs, J.; Chargari, C.; Smeulders, N.; Granberg, C. F.; Wolden, S. L.; Sparber-Sauer, M.; Hawkins, D. S.; Bisogno, G.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the PALOMA-2 trial
    Journal Article

    Merola, D.; Young, J.; Schrag, D.; Lin, K. J.; Alwardt, S.; Schneeweiss, S.
    Pharmacoepidemiology and Drug Safety (2023)

    Fulltext@MSK | Save
  • Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
    Journal Article

    Matsubara, N.; Yonese, J.; Kojima, T.; Azuma, H.; Matsumoto, H.; Powles, T.; Rosenberg, J. E.; Petrylak, D. P.; Matsangou, M.; Wu, C.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save
  • Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
    Journal Article

    Yoshino, T.; Andre, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; more...
    Cancer Science (2023)

    Fulltext@MSK | Save
  • Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: A propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
    Journal Article

    Weber, J. S.; Poretta, T.; Stwalley, B. D.; Sakkal, L. A.; Du, E. X.; Wang, T.; Chen, Y.; Wang, Y.; Betts, K. A.; Shoushtari, A. N.
    Cancer Immunology, Immunotherapy (2023)

    Fulltext@MSK | Save